Vividion Names Patty Allen as Full-Time Chief Financial Officer and Welcomes Brian Koh, M.D., as Head of Translational Sciences and Clinical Development
SAN DIEGO--(BUSINESS WIRE)-- Vividion Therapeutics, Inc.., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Patricia “Patty” Allen, who has served as acting chief financial officer of Vividion since January 2021, has joined the company as full-time CFO and that Brian Koh, M.D., has been appointed as head of translational sciences and clinical development.
“Vividion has been making significant progress advancing our programs for the treatment of patients with cancer and immunologic disorders, and as we grow, the strength of our team is more important than ever,” said Jeffrey Hatfield, chief executive officer of Vividion. “Patty has been instrumental in the execution of our financial strategy, including the successful completion of a $135 million Series C financing, and I am thrilled that she will join us in a full-time capacity. In addition, Brian’s expertise in leading product candidates through various stages of clinical development and his knowledge of protein modulation will be critical to our success as we advance toward IND-enabling studies and the clinic.”
Ms. Allen is a business finance and operations leader with more than 25 years of experience leading and advising financial and investor relations functions at private and public companies. She previously served in financial related roles of increasing responsibility within the biotechnology industry, including at Alnylam, Alkermes and Zafgen, where across those positions, she played an influential role in raising more than $1 billion in private and public offerings. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP, after graduating summa cum laude from Bryant College with a B.S. in business administration.
“I have been incredibly inspired by Vividion’s scientific approach and the drive of the team, which I believe position us for a bright and successful future,” said Ms. Allen. “The integration of our proprietary platform with deep chemistry and biology capabilities, positions us at the forefront of developing medicines that address targets in oncology and immunology indications that have long been known as undruggable. Our approach could make a true difference for patients, and I am honored to continue to support Vividion as we grow.”
Dr. Koh previously served in positions of increasing responsibility at both Gilead Sciences and Kite Pharma, leading programs and studies spanning early through late stages of clinical development of targeted, immuno-oncological and cellular therapies in both solid and hematological malignancies. He received an M.D. as well as an M.S. and M.Phil. from Yale University, the latter for graduate work in chemical biology. At Mayo Clinic-Rochester, he completed a postdoctoral fellowship in clinical pharmacology as well as postgraduate medical education in internal medicine, hematology and medical oncology, while holding a triple academic appointment as an instructor in the departments of medicine, oncology and pharmacology.
“I am very excited to join this team of passionate and talented individuals to advance Vividion’s highly innovative science and platform, as I believe it offers a singular opportunity to drive the efficient development of novel and effective therapies to address great unmet medical need,” said Dr. Koh.
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. For more information, please visit www.vividion.com.
THRUST Strategic Communications
Source: Vividion Therapeutics, Inc.